A comparison of patient survival and tumour growth kinetics in human bronchogenic carcinoma.
A series of 46 primary bronchogenic carcinomas for which thymidine labelling index (%TLI) (in all cases) and tumour doubling time (DTact) (in 13 cases) had previously been measured were followed up for 5 years and these data compared with length of post operative survival, tumour volume at operation and pathological staging. We found no correlation between reduced survival and higher tumour %TLI, indeed the reverse may be true. Larger tumours tended to have higher labelling indices considering either primary tumour volume or 'T'-category. Five year survivors had smaller tumours, tended to have T1 tumours and Stage I disease but did not have significantly lower tumour %TLIs. No relationship was found between DTact and any other parameter.
Kerr
K M
KM
Department of Pathology, Edinburgh University Medical School, UK.
Lamb
D
D
D000230:Adenocarcinoma / Q000473:pathology; D002283:Carcinoma, Bronchogenic / Q000401:mortality / Q000473:pathology*; D018288:Carcinoma, Small Cell / Q000473:pathology; D002294:Carcinoma, Squamous Cell / Q000473:pathology; D002455:Cell Division; D006801:Humans; D008175:Lung Neoplasms / Q000401:mortality / Q000473:pathology*; D008938:Mitosis; D009367:Neoplasm Staging; D013936:Thymidine / Q000378:metabolism; D013997:Time Factors
D013936:Thymidine